Celldex Therapeutics Inc. announced new data from the Phase 2 open-label extension of its inducible urticaria program showing that retreatment with barzolvolimab after symptom recurrence produced response rates similar to initial treatment in patients with cold urticaria and symptomatic dermographism. At Week 20 of the extension, 62% of cold urticaria patients and 60% of symptomatic dermographism patients achieved a complete response, and the safety profile was reported as consistent with prior studies. The results were presented as a late-breaking poster at the 2026 American Academy of Allergy, Asthma and Immunology Annual Meeting. Celldex also noted that its global Phase 3 EMBARQ trial in these indications began enrolling in late 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Celldex Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603010945PRIMZONEFULLFEED9663441) on March 01, 2026, and is solely responsible for the information contained therein.